» Articles » PMID: 16270046

Differential Expression of NF-kappaB Pathway Genes Among Peripheral T-cell Lymphomas

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2005 Nov 5
PMID 16270046
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Nuclear factor kappa B (NF-kappaB) is one important pathway in T-cell proliferation and survival. In a previously reported microarray study, we found NF-kappaB pathway genes differentially expressed between peripheral (PTCL) and lymphoblastic lymphomas. Here, we investigated the expression of NF-kappaB pathway genes using cDNA microarrays in a group of 62 PTCL and in reactive lymph nodes. We found two different subgroups of PTCL based on the expression of NF-kappaB pathway genes. One-third of PTCL showed clearly reduced expression of NF-kappaB genes, while the other group was characterized by high expression of these genes. This distinction was found among all T-cell lymphoma categories analyzed (PTCL unspecified, angioimmunoblastic, cutaneous and natural killer/T lymphomas) with the exception of anaplastic lymphomas (ALCL), which were characterized by reduced NF-kappaB expression in anaplastic cells. Quantitative RT-PCR and immunohistochemical analysis of NF-kappaB-p65 protein confirmed these differences among PTCL subgroups. Importantly, we found that differentiation between NF-kappaB-positive and -negative PTCL could be of clinical interest. The expression profile associated to reduced expression of NF-kappaB genes was significantly associated with shorter survival of patients and seems to be an independent prognostic factor in a multivariate analysis.

Citing Articles

New insights into the biology of T-cell lymphomas.

Iqbal J, Inghirami G, Chan W Blood. 2024; 144(18):1873-1886.

PMID: 39213420 PMC: 11551850. DOI: 10.1182/blood.2023021787.


Peripheral T-Cell Lymphoma, Not Otherwise Specified: Clinical Manifestations, Diagnosis, and Future Treatment.

Pileri S, Tabanelli V, Fiori S, Calleri A, Melle F, Motta G Cancers (Basel). 2021; 13(18).

PMID: 34572763 PMC: 8472517. DOI: 10.3390/cancers13184535.


Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified.

Debackere K, Marcelis L, Demeyer S, Vanden Bempt M, Mentens N, Gielen O Nat Commun. 2021; 12(1):3705.

PMID: 34140493 PMC: 8211700. DOI: 10.1038/s41467-021-24037-4.


induces NF-κB signaling-driven peripheral T cell lymphoma.

Moon C, Reglero C, Cortes J, Quinn S, Alvarez S, Zhao J Nat Cancer. 2021; 2(1):98-113.

PMID: 33928261 PMC: 8081346. DOI: 10.1038/s43018-020-00161-w.


Proliferative, pro-inflammatory, and angiogenesis regulator gene expression profile defines prognosis in different histopathological subtypes of nodal peripheral T-cell lymphoma.

Lage L, Levy D, Xavier F, Reis D, Costa R, Goncalves M Oncotarget. 2019; 10(50):5136-5151.

PMID: 31497245 PMC: 6718262. DOI: 10.18632/oncotarget.27098.